Insider · CIK 0001486099
Christopher Galletta
officer
Files at TRVI (Trevi Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 2, 2025 | TRVI Trevi Therapeutics, Inc. | MOption exercise Common Stock | +4,225 | $0.51 | $2,159 | 26,095 | Dec 3, 2025 |
| Dec 2, 2025 | TRVI Trevi Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -4,225 | $0.00 | $0 | 15,775 | Dec 3, 2025 |
| May 31, 2025 | TRVI Trevi Therapeutics, Inc. | AGrant or award Performance Stock Option (right to buy)derivative | +8,550 | $0.00 | $0 | 13,110 | Jun 3, 2025 |
| Mar 10, 2025 | TRVI Trevi Therapeutics, Inc. | AGrant or award Performance Stock Option (right to buy)derivative | +4,560 | $0.00 | $0 | 4,560 | Mar 12, 2025 |
| Feb 18, 2025 | TRVI Trevi Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +41,000 | $0.00 | $0 | 41,000 | Feb 20, 2025 |
| Dec 13, 2024 | TRVI Trevi Therapeutics, Inc. | MOption exercise Common Stock | +15,000 | $0.51 | $7,665 | 19,935 | Dec 17, 2024 |
| Dec 13, 2024 | TRVI Trevi Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -15,000 | $0.00 | $0 | 20,000 | Dec 17, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.